Bonnie Bassler - Regeneron Pharmaceuticals Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 15px;;'>RE</div>
REGN -- USA Stock  

Earning Report: February 6, 2020  

  Director
Dr. Bonnie Bassler, Ph.D., is an Independent Director of the Company. Dr. Bassler is currently the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University, and a Howard Hughes Medical Institute Investigator. Dr. Bassler has previously served as the President of the American Society for Microbiology, as well as on the boards for the American Association for the Advancement of Science, the National Science Foundation, and the American Academy of Microbiology. She was elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the Royal Society of London, and the American Philosophical Society, and has received many scientific honors, including a MacArthur Foundation Fellowship, the Lounsbery Award, and the Shaw Prize for Life Science and Medicine. Dr. Bassler received her B.Sc. from the University of California, Davis, and her Ph.D. in Biochemistry from Johns Hopkins University. She served as a Postdoctoral Fellow and Research Scientist at the Agouron Institute in La Jolla, CA, before becoming a faculty member at Princeton University
Age: 55  Director Since 2016      
914 847-7000  www.regeneron.com
Bassler served as a director of Sanofi from November 2014 to July 2016.

Bonnie Bassler Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 23.16 % which means that it generated profit of $23.16 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 31.86 % meaning that it created $31.86 on every $100 dollars invested by stockholders.
The company currently holds 738 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

James KangOrigin Agritech Limited
2010
Bradley AlfordPerrigo Company Plc
2017
William YoungVertex Pharmaceuticals Incorpor
2014
Michael JandernoaPerrigo Company Plc
2007
Kalpana MorpariaDr Reddys Laboratories Ltd
2007
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Theodore SamuelstoPerrigo Company Plc
2017
Ravi BhoothalingamDr Reddys Laboratories Ltd
2000
Adriana KaraboutisPerrigo Company Plc
2017
Larry CordellOrigin Agritech Limited
2012
Theodore SamuelsPerrigo Company Plc
2017
Michael TrimbleOrigin Agritech Limited
2006
Willie ReedZoetis
2014
J MoreauDr Reddys Laboratories Ltd
2007
Jeffrey KindlerPerrigo Company Plc
2017
Geoffery MerszeiOrigin Agritech Limited
2016
Linda RhodesZoetis
2017
Allan ObermanDr Reddys Laboratories Ltd
2019
Gregory NordenZoetis
2013

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7674 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,674 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module

Currently Active Assets on Macroaxis

MS   
Purchased over 90 shares of
few hours ago
Traded for 53.0
LMT   
Purchased few shares of
few hours ago
Traded for 414.94
JPM   
Purchased over 100 shares of
few hours ago
Traded for 138.0
JKHY   
Purchased over 20 shares of
few hours ago
Traded for 152.45
ITOT   
Purchased over 40 shares of
few hours ago
Traded for 75.05
Additionally take a look at Your Equity Center. Please also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.